Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956590 · ClinicalTrials.gov registry record · Phase 3
Dyslipidemia of Obesity Intervention in Teens
A Phase 3 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
NCT02956590 is a Phase 3 study that has completed, run by Carelon Research. The registered enrollment target is 122 participants.
The verdict
NCT02956590, a Phase 3 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
Study Summary
This trial of pitavastatin will determine efficacy and safety in this high risk population and provide evidence for clinicians to target this treatable risk factor to achieve an impact on early atherosclerosis, and potentially achieve primary prevention of adult cardiovascular disease.
Interventions
- DRUG Placebo
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956590
The ClinicalTrials.gov registry entry for NCT02956590 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02956590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956590 about?
NCT02956590 is a clinical study titled "Dyslipidemia of Obesity Intervention in Teens". This trial of pitavastatin will determine efficacy and safety in this high risk population and provide evidence for clinicians to target this treatable risk factor to achieve an impact on early atherosclerosis, and potentially achieve primary prevention of adult cardiovascular disease.
What is the current status of trial NCT02956590?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2018-05-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT02956590?
The interventions under investigation include: Placebo (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT02956590?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.